CRISPR Therapeutics AG (CRSP)
46.29
-0.97
(-2.05%)
USD |
NASDAQ |
Nov 21, 16:00
46.55
+0.26
(+0.56%)
Pre-Market: 09:01
CRISPR Therapeutics Total Liabilities (Quarterly): 316.47M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 316.47M |
| June 30, 2024 | 358.90M |
| March 31, 2024 | 355.08M |
| December 31, 2023 | 346.77M |
| September 30, 2023 | 359.04M |
| June 30, 2023 | 380.99M |
| March 31, 2023 | 389.47M |
| December 31, 2022 | 367.58M |
| September 30, 2022 | 399.40M |
| June 30, 2022 | 372.53M |
| March 31, 2022 | 361.26M |
| December 31, 2021 | 352.42M |
| September 30, 2021 | 308.80M |
| June 30, 2021 | 295.72M |
| March 31, 2021 | 152.41M |
| December 31, 2020 | 163.73M |
| September 30, 2020 | 141.72M |
| June 30, 2020 | 135.86M |
| Date | Value |
|---|---|
| March 31, 2020 | 121.20M |
| December 31, 2019 | 127.33M |
| September 30, 2019 | 128.71M |
| June 30, 2019 | 126.56M |
| March 31, 2019 | 118.06M |
| December 31, 2018 | 96.82M |
| September 30, 2018 | 101.59M |
| June 30, 2018 | 87.98M |
| March 31, 2018 | 84.12M |
| December 31, 2017 | 83.51M |
| September 30, 2017 | 103.36M |
| June 30, 2017 | 107.17M |
| March 31, 2017 | 107.17M |
| December 31, 2016 | 112.12M |
| September 30, 2016 | 341.18M |
| June 30, 2016 | 157.72M |
| December 31, 2015 | 188.55M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
121.20M
Minimum
Mar 2020
399.40M
Maximum
Sep 2022
290.33M
Average
349.59M
Median
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 6.609B |
| AC Immune SA | 135.61M |
| Addex Therapeutics Ltd | 1.164M |
| NLS Pharmaceutics Ltd | 10.46M |
| Molecular Partners AG | 18.34M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.256B |
| Shareholders Equity (Quarterly) | 1.940B |